Abstract:In the past decade, a growing body of evidence has shown that HBsAg quantification (qHBsAg) not only is a useful marker for monitoring natural history of treatment-naïve Chronic HBV Infection (CHB) but can also predict clinical and treatment outcomes [1]. While, other study indicated that, being used alone, qHBsAg is not a suitable marker for evaluating hepatitis activity and distinguishing between cases of HBeAg-negative CHB and inactive HBV carrier state [2]. In our study, we showed that qHBsAg had high predictive value for discrimination of immune tolerance (IT) and Immune Clearance (IC) phase, and it had moderate predictive value for differentiation of low replication (LR) phase and HBeAg Negative Hepatitis (ENH) [3]. While, role of HBeAg quantification (qHBeAg) in natural phases of HBV infection has not been attracted more attention up to now. We found that in HBeAg positive phase of treatment-naïve CHB, qHBsAg and qHBeAg correlated positively (P<0.0001), and both had strong negative correlation with grade of liver inflammation (G) (P<0.0001) and Fibrosis stage (F) (P<0.0001) (unpublished data). Thus, we might speculate that qHBeAg can either be used as a marker of natural phases of HBV infection in HBeAg positive patients. Indeed, we demonstrated that qHBeAg had moderate predictive value for discriminating IT and IC phase [3]. And qHBsAg and qHBeAg had moderate predictive value for F1, F2 and F3 and for G2 and G3 in treatment-naïve HBeAg positive CHB (unpublished data). In recent years, HBcAb quantification (qHBcAb) has been indicated to be associated with HBV infection induced hepatitis [4]. We also suggested that qHBcAb are higher in IC and ENH phases than in IT and LR phases. And qHBcAb correlated positively with grade of liver inflammation. Whereas, the qHBcAb has low divisional value for the intermediate grades of inflammation (unpublished data). Next, we will determine whether qHBcAb is different with liver injury of different etiologies in HBV infection, including HBV infection merged with non-alcoholic fatty liver disease or combined with drug induced liver injury. In all, qHBsAg had high and qHBeAg had moderate predictive value for discrimination of IT and IC phase. And both had moderate predictive value for diagnosis of mild to severe liver fibrosis in treatment-naïve HBeAg positive CHB. Both qHBsAg and qHBcAb had moderate predictive value for differentiation of LR and ENH phase.

Predictive Value of Hepatitis B Core-Related Antigen (HBcrAg) During the Natural History of Hepatitis B Virus Infection.

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

HBcrAgandpgRNAand the therapeutic effect inHBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNAis a powerful predictor of response.

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Distinct Patterns of Serum Hepatitis B Core-Related Antigen During the Natural History of Chronic Hepatitis B

Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis.

Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients

Clinical Diagnostic Value of Quantitative Hepatitis B Virus Core Antibody Test in Chronic Viral Hepatitis B

Clinical Significance of Novel Biomarkers to Predict the Natural Course of Hepatitis B Infection.

Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

Quantitative Serum HBV Markers in Predicting Phases of Natural History of Chronic HBV Infection.

Characteristics of HBV Novel Serum Markers Across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients

Comparison of Hepatitis B Virus Core-Related Antigen and Hepatitis B Surface Antigen for Predicting HBeAg Seroconversion in Chronic Hepatitis B Patients with Pegylated Interferon Therapy.

Role of Serum Hepatitis B Virus Marker Quantitation to Differentiate Natural History

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Serum Hepatitis B Core-Related Antigen is A Satisfactory Surrogate Marker of Intrahepatic Covalently Closed Circular Dna in Chronic Hepatitis B

The Role of Hepatitis B Core-Related Antigen in Predicting Hepatitis B Virus Recurrence after Liver Transplantation.

Capabilities of Hepatitis B Surface Antigen Are Divergent from Hepatitis B Virus DNA in Delimiting Natural History Phases of Chronic Hepatitis B Virus Infection

Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study.

Characteristics of Hepatitis B Core Antibody Level in the Natural History of Chronic Hepatitis B.